Menu
Menu
You are invited to join our networking event on hematologic malignancies during the 2026 Association of Molecular Pathologists Annual Meeting & Expo in Seattle, USA.
Connect with peers and leading experts to explore how NGS-based solutions are helping labs keep pace with evolving guidelines and deliver meaningful insights while keeping their workflow efficient and cost-effective.
During this event, speakers from renowned institutions will share real-world experiences implementing high-sensitivity applications and translating complex molecular findings to real clinical impact.
This is your opportunity to learn how peers are overcoming complexity across the entire workflow, from library prep, to patient-centered interpretation.
About the Event
What: An Educational Networking Dinner
Where: Renaissance Seattle Hotel
Date: Wednesday, November 11th
Time: 6:30 pm – 8:15pm
Agenda
From Assay Development to Clinical Utility: High-Sensitivity Clonal Hematopoiesis Testing
Gang Zheng, M.D., Ph.D.
Co-director Clinical Genomics Laboratory, Professor of Laboratory Medicine and Pathology, Mayo Clinic
Lessons from a molecular tumor board
Todd C. Knepper, PharmD
Associate Member in Precision Oncology, Department of Pathology, Moffitt Cancer Center
Reserve your seat to this exclusive event on Wednesday, November 11th starting at 6:30 pm.
SOPHiA GENETICS is thrilled to attend this year's Association for Molecular Pathology (AMP) Annual Meeting at the Seattle Convention Center!
Find us at Booth #715 to explore how SOPHiA DDM™ is advancing precision oncology across comprehensive solid tumor profiling and hematologic malignancies, with AI-powered analytics that transform complex data into actionable insights.
Corporate Workshop: One Integrated Workflow from Tissue to Liquid Biopsy: Real-World Insights on MSK-IMPACT® Flex and MSK-ACCESS® powered with SOPHiA DDM™
Wednesday, November 11 – 8:00 AM – 8:50 AM
Skagit 5, Lower Level, Arch at 800 Pike
Speakers:
Andrew Fellowes – Lead Scientist, Molecular Diagnostic Development, Peter MacCallum Cancer Center
Lina Li, Product Marketing Director – Solid Tumors, SOPHiA GENETICS
Corporate Workshop: Scaling Decentralized Pan-Cancer Liquid Biopsy: Multicentric Validation of MSK-ACCESS® powered with SOPHiA DDM™
Wednesday, November 11 – 9:00 AM – 9:50 AM
Skagit 5, Lower Level, Arch at 800 Pike
Speaker:
Florian Klemm, Technical Product Management Expert, SOPHiA GENETICS
Blood Cancer Showcase: The Next Frontier in Blood Cancer Genomics
Wednesday, November 11 – 6:30 PM
Venue TBD, Seattle
Join SOPHiA GENETICS for an evening, dedicated to advances in blood cancer, diagnostics, and precision oncology.
Agenda:
Brandon Bullough - Product Marketing Director, Blood Cancers, SOPHiA GENETICS
Gang Zheng, M.D., Ph.D. - Co-director Clinical Genomics Laboratory, Professor of Laboratory Medicine and Pathology, Mayo Clinic
Todd C. Knepper, PharmD - Associate Member in Precision Oncology, Department of Pathology, Moffitt Cancer Center
Poster Presentations
Saturday, November 14 – 9:15 – 10:15 AM
Presenter: Florian Klemm, Technical Product Management Expert, SOPHiA GENETICS
Co-authors: Fuad Mohammad, Jonathan Bieler, Frederic Michaud, Anjali Anjali, Alex Charles Tuck, Saraj Figarol, Anne Pradines, Laura Keller, Maryline Allegra, Guylene Rignol, Paul Hofman, Caroline Lacoux, Laurie Canetti, Emeline Jorge, Frédérique Penault-Llorca, Marie-Celeste Ferreira, Rochelle Awuku, Alasdair Heasman, Gareth Gerrard, Persephone Du-Parcq, Gaëlle Lescuyer, Marie Piecyk, Lea Payen, Tessara Baldi, Anita Bowman, Rose Brannon, Michael Berger, Zhenyu Xu
Presenter: Slawomir Kubik, Head of Technical Product Management – Oncology, SOPHiA GENETICS
Co-authors: Christian Pozzorini, Alexis Bachmann, Gregoire Andre, Frederic Michaud, Elia Magrinelli, Tommaso Coletta, Yvan Wenger, Adrian Willig, Kevin Green, Benjamin Krajacich, Marina McCowin, Kelly Wiseman, Junhua Zhao, Zhenyu Xu
Plan your AMP visit
Whether you're working in solid tumor profiling, liquid biopsy, or hematologic malignancies, we'd love to connect and learn more about the challenges your laboratory is working to solve.
Meeting slots at AMP fill quickly. Book time with our team before you arrive in Seattle.
See you there! 🧬
Genomics is changing how we understand cancer
The next chapter is about turning insight into action.
Precision oncology is entering a new era.
As next-generation sequencing, liquid biopsy and advanced genomic technologies continue to evolve, the opportunity is no longer simply to generate more data — but to translate increasingly complex genomic information into clinically meaningful insights.
Insights that can help us:
Join SOPHiA GENETICS for an evening of expert discussion exploring the next chapter in precision oncology — where genomic data, clinical expertise and innovation converge to bring precision medicine closer to the patient.
DR. KOJO S. ELENITOBA-JOHNSON, MD
Chair, Department of Pathology and Laboratory Medicine
Memorial Sloan Kettering Cancer Center
Dr. Kojo S. Elenitoba-Johnson is a physician-scientist specialising in hematopathology and molecular genetic pathology, with more than three decades of experience in pathology and molecular pathology.
His work focuses on genomic and proteomic alterations in lymphoma and their diagnostic and therapeutic applications, including the use of advanced genomic approaches such as next-generation sequencing in hematologic malignancies.
DR. OMShree
Scientific Officer, Molecular Diagnostics & Translational Medicine
Tata Memorial Centre
Dr. Omshree brings a clinical and translational perspective from Tata Memorial Centre, one of India's leading institutions in cancer care, research and education.
Her work contributes to the evolving role of molecular diagnostics and genomic medicine in cancer, and how advances in genomics can translate into meaningful clinical practice and patient care.
DR. SRIDHAR SIVASUBBU
Chief Diagnostics & Research Officer & Lab Director
Karkinos Healthcare
Dr. Sridhar Sivasubbu brings extensive expertise across genomics, molecular diagnostics and precision medicine, with a strong focus on translating genomic science into healthcare.
At Karkinos Healthcare, his work sits at the intersection of diagnostics, research and cancer genomics. He has also been involved in initiatives such as the Bharat Cancer Genome Atlas, supporting the development of genomic resources to advance cancer research and more personalised approaches to cancer care in India.
13 October 2026 | 3:00 PM | Prince Court Medical Centre (PCMC), Kuala Lumpur
Join leading voices from across Malaysia’s healthcare and oncology community for an afternoon exploring how precision oncology can move from vision to clinical impact.
Hear perspectives from IHH, the Ministry of Health, SOPHiA GENETICS and leading clinicians on the evolution of precision oncology in Malaysia — from genomic insights and AI-powered innovation to real-world clinical practice.
A Milestone for Precision Oncology
A key highlight of the afternoon will be the Memorandum of Understanding signing between Premier Integrated Labs (PIL) and SOPHiA GENETICS, marking a shared commitment to advancing precision medicine and strengthening Malaysia’s precision oncology ecosystem.
The programme will also feature clinical cases, expert perspectives and opportunities to connect with colleagues shaping the future of cancer care.
Programme
| Session | Activity |
|---|---|
| Opening | Shaping the Future of Precision Oncology in Malaysia |
| IHH Keynote | IHH’s Vision for Precision Oncology and the Future of Cancer Care |
| MOH | Malaysia’s Precision Oncology Journey: From Vision to Access |
| SOPHiA GENETICS | AI-Powered Precision Oncology: From Genomic Data to Clinical Impact |
| MOU Signing | PIL × SOPHiA GENETICS: A Partnership for the Future of Precision Oncology |
| Clinical Cases | Precision Oncology in Practice: From Genomic Insights to Patient Care |
| Networking | Building the Precision Oncology Ecosystem in Malaysia |
Register your Interest
We would be delighted to have you join us for this important milestone in Malaysia’s precision oncology journey.
El próximo 15 de octubre, en las instalaciones de INMEGEN, se llevará a cabo el GENOMiCS INSIGHTS Day México, un encuentro que reunirá a líderes clínicos, investigadores y especialistas en genómica para compartir experiencias y discutir el papel creciente de la medicina de precisión en la atención de pacientes oncológicos.
Durante la jornada se abordarán temas clave como los avances en programas de prevención y vigilancia genómica, la evolución del perfilamiento molecular desde tejido hasta biopsia líquida, y la implementación de programas de secuenciación a gran escala en instituciones de referencia internacionales. Asimismo, se presentarán experiencias regionales sobre el uso de la biopsia líquida para apoyar la toma de decisiones terapéuticas en cáncer y casos reales de adopción de tecnologías genómicas en la práctica clínica.
El evento contará con ponentes de reconocidas instituciones de México, Estados Unidos y Brasil, quienes compartirán perspectivas clínicas, operativas y científicas sobre la integración de la genómica en los sistemas de salud. La jornada finalizará con una mesa redonda y un espacio de networking, promoviendo el intercambio de conocimientos y la colaboración entre los profesionales de la región.
What: SOPHiA GENETICS exclusive networking event
Date: 15 de octobre
Time: 8h:30-13h:30
Where: INMEGEN
8:30 – 09:00
Registration
9:00 – 09:15
Opening
9:15 – 9:45
Cuando la genómica se convierte en prevención.
Avances y resultados de la Estrategia de Vigilancia Anticipada EVA
Carmen Alaez, MSc, PhD.
Head of Genomic Diagnostics Department
INMEGEN, México
9:45 – 10:30
From Tissue to Blood: The Evolution and Spectrum of Precision Profiling at MSK
Anita Bowman, MSc
Associate Director - Clinical Bioinformatics
Memorial Sloan Kettering Cancer Center, USA
10:30 – 11:00
Coffee Break
11:00 - 11:20
Implementation of the MSK-ACCESS test at a reference oncology hospital in Brazil
Mariana Vargas Cruz, MSc, PhD
Scientific Advisor
Hospital Sírio-Libanês, Brazil
11:20 – 11:40
Biopsia líquida: del biomarcador a la decisión terapéutica en cáncer de próstata y pulmón
Melania Abreu, MD
Clinical Geneticist
Genos Médica, México
11:40 - 12:30
Roundtable
12:30 – 13:30
Refreshements and Networking
Conozca cómo SOPHiA DDM™ permite realizar análisis precisos en diversas áreas de la medicina, desde oncología hasta enfermedades raras.
Participe en una conversación sobre el futuro de las instituciones de salud e investigación y descubra cómo aprovechar el potencial de los datos de secuenciación de nueva generación (NGS) para generar resultados rápidos, sólidos y accionables que faciliten una toma de decisiones informada.
Interactúe con colegas, investigadores y usuarios de la plataforma SOPHiA DDM™ en un espacio diseñado para el intercambio de conocimientos, experiencias y oportunidades de colaboración científica.
Le invitamos a participar en el exclusivo GENOMiCS INSIGHTS DAY Uruguay, que se llevará a cabo el próximo 22 de octubre en el Radisson Hotel.
El evento contará con la participación de especialistas y clientes que compartirán su experiencia real en la práctica clínica, abordando temas de alto impacto: desde la aplicación del NGS en oncología y hematología hasta el panorama actual del cáncer hereditario en Latinoamérica.
La jornada reunirá experiencias concretas de clientes que utilizan la plataforma SOPHiA DDM™ en su día a día, ofreciendo una perspectiva directa sobre su impacto en el diagnóstico molecular y la toma de decisiones clínicas. El evento culminará con una mesa redonda y un espacio de cocktails y networking, ideal para el intercambio de conocimientos y oportunidades de colaboración.
A continuación, encontrará la agenda preliminar del evento
What: SOPHiA GENETICS exclusive networking event
Date: 22 de octobre
Time: 19h:00-22h:00
Where: Radisson Hotel
19:00 – 19:30
Una Red Global de Inteligencia Genómica:
Presentamos SOPHiA GENETICS
Daniel Acevedo
Sales executive, South LATAM
SOPHiA GENETICS
19:30 – 20:00
Genómica aplicada a la hematología: experiencia del Hospital de Clínicas con paneles SOPHiA GENETICS
Sofía Grille, MD, PhD.
Profesora Titular y Directora de la Unidad Académica de Hematología, Hospital de Clínicas, Universidad de la República, Uruguay
20:00 – 20:30
NGS en la práctica oncológica: experiencia del Hospital Maciel en cáncer de pulmón y colorrectal.
Juan Martín Marques, PhD.
Director Científico del Laboratorio de Oncología Molecular del Hospital Maciel. Líder de Servicios de NGS, Laboratorio de Biología Molecular del Sanatorio Americano , Uruguay
20:30 - 21:00
Rastreando el Cáncer: Del Riesgo Hereditario a la Detección en Tiempo Real
Bruno Piovezan, Msc.
Subject Matter Expert LATAM
SOPHiA GENETICS
21:00 – 21:30
Sesión de Mesa Redonda
21:30 – 22:00
Cocktails & Networking
Conozca cómo SOPHiA DDM™ permite realizar análisis precisos en diversas áreas de la medicina, desde oncología hasta enfermedades raras.
Participe en una conversación sobre el futuro de las instituciones de salud e investigación y descubra cómo aprovechar el potencial de los datos de secuenciación de nueva generación (NGS) para generar resultados rápidos, sólidos y accionables que faciliten una toma de decisiones informada.
Interactúe con colegas, investigadores y usuarios de la plataforma SOPHiA DDM™ en un espacio diseñado para el intercambio de conocimientos, experiencias y oportunidades de colaboración científica.
📍 National Institutes of Health (NIH), Kuala Lumpur, Malaysia | ⏱️ 2-hour session (10am - 12pm) | 8 October 2026
An exclusive educational session for government laboratory specialists, bioinformaticians, and pathologists
About This Session
As genomic testing volumes continue to rise across public healthcare systems, laboratories are under increasing pressure to deliver faster, more consistent, and more clinically actionable results.
SOPHiA GENETICS, in partnership with Science Vision, invites government stakeholders at the forefront of genomic diagnostics in Malaysia to a dedicated educational session, offering a substantive discussion of the analytical and interpretive challenges facing genomic laboratories today, and how AI-powered platforms such as SOPHiA DDM™ are helping address them.
Participants will gain practical insight into modern genomic workflows, observe the platform in a live demonstration, and have the opportunity to contribute their own laboratory's challenges to the discussion.
Why Attend
Agenda
| Agenda |
|---|
| Welcome & Stakeholder Introductions |
| How SOPHiA DDM™ Tackles Real-World Genomic Challenges |
| Live Platform Demo — See SOPHiA DDM™ in action, from sample to report |
| User Experience Sharing |
| Open Discussion & Q&A |
Who Should Attend
Government laboratory specialists, bioinformaticians, pathologists, and public healthcare stakeholders involved in genomic testing and analysis.
Join us at the 2026 ASHG Annual Meeting in Montreal to explore how SOPHiA DDM™ supports genomic analysis and interpretation across rare and inherited disorders, including hereditary cancer, and pharmacogenomics.
Visit us at Booth #517 to connect with our genomics experts, experience SOPHiA DDM™ firsthand and discover how a data driven approach can help laboratories streamline complex genomic workflows and turn data into meaningful insights.
More ways to connect with us at ASHG
Join us at our CoLab
Hear about Trillium Health Partners’ approach to PMS2/PMS2CL disambiguation and see the latest data for our enhanced exome solutions.
Friday, October 23 | 10.15-10.45 | CoLab Theatre 2
Explore our poster presentation
Comprehensive detection of SNVs / Indels, CNVs and complex gene conversions across germline applications using an enhanced exome approach
Authors: Tamara Maas, Yuanlong Liu, Bita Khalili, Dmitri Ivanov, Alfredo Mari, Jian Yu, Rieke Kempfer, Zhenyu Xu
Wednesday, October 21, 2:30-4:30 EDT
Discover new data and insights from our latest work.
Plan your ASHG visit
Whether you're working on rare disorders, hereditary cancer, or pharmacogenomics, we'd love to connect and learn more about the challenges your laboratory is working to solve.
Meeting slots at ASHG fill quickly. Book time with our team before you arrive in Montreal.
See you there. 🧬
Join SOPHiA GENETICS at SFMPP 2026 in Paris, France! Come meet our team of experts at Booth #16. We are looking forward to discussing how we support laboratories and healthcare institutions with scalable, data-driven solutions. Check out our full program below:
The SOPHiA GENETICS team will be happy to see you join our Flash Symposium on Friday, 9 October from 12:35-12:50PM in the PLÉNIÈRE Room.
“Optimisation des flux d’analyse NGS en oncologie solide : retour d’expérience d’un service de Pathologie”
Speakers:
In this session, Benjamin will share how his team is optimizing NGS analysis workflows in solid tumor oncology, covering the challenges of implementing NGS in routine clinical practice and the impact on turnaround time and workflow efficiency.
SOPHiA GENETICS is proud to join the 37th CBGM in São Luís, Maranhão (Sept 2–5, 2026), celebrating 40 years of SBGM and the future of precision medicine in Brazil. Meet us at Booth #20 to discover the latest innovations of the New Generation SOPHiA DDM™ Platform, with a special focus on Exome advancements.
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.